Journals / The Journal of Pediatric Research / 2018 / Cilt: 5 - Sayı: 1

An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis

Pages
12–16
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Curative gene therapy may be available in the future.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The purpose of our study is to submit the demographic, phenotypic and age at diagnosis characteristics of children with GM2 gangliosidosis.Materials and Methods: Patients with GM2 gangliosidosis who were referred to Ege University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Nutritionand Metabolism between January 2004 and December 2016, were included in this study.
📊
Key Findings & Data:The demographic and clinical features are reported for 8 patients with Tay-Sachs disease (TSD) and 6 with Sandhoff disease.Results: The mean age at diagnosis was 18.2 months (range 4-48 months) and 14.5 months (range 8-36 months) for patients with TSD or Sandhoff disease respectively.
💡
Conclusion & Impact:Curative gene therapy may be available in the future.
🔬Design:Research Article
📍Scope:2004 Verileri
⚙️Variables:Domain Parameters

Özet

Aim: The purpose of our study is to submit the demographic, phenotypic and age at diagnosis characteristics of children with GM2 gangliosidosis.Materials and Methods: Patients with GM2 gangliosidosis who were referred to Ege University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Nutritionand Metabolism between January 2004 and December 2016, were included in this study. Diagnosis was confirmed by determining the level of serum β-hexosaminidaseactivity and genetic mutation analysis. The demographic and clinical features are reported for 8 patients with Tay-Sachs disease (TSD) and 6 with Sandhoff disease.Results: The mean age at diagnosis was 18.2 months (range 4-48 months) and 14.5 months (range 8-36 months) for patients with TSD or Sandhoff disease respectively. Theinitial and main complaint in 100% of the patients were neurological disorders, such as developmental delay, developmental regression or both; seizures and macrocephaly.None of the patients exhibited evidence of organomegaly. Cranial magnetic resonance imaging results were normal in 36% of the cases, 55% of the cases had bilateral thalamiinvolvement presenting as T2 hyperintensity especially at the posterior thalami and 9% of cases had myelination delay.Conclusion: GM2 gangliosidosis disease should be considered for children with developmental regression and/or delay. To prevent a delay in diagnosis, β-hexosaminidaseactivity in serum and genetic mutation analysis should be undertaken in suspected cases. Curative gene therapy may be available in the future.

🔖

Cite This Article

ER, E., CANDA, E., YAZICI, H., ERASLAN, C., SÖZMEN, E. Y., UÇAR, S. K., ÇOKER, M. (2018). An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis. The Journal of Pediatric Research, Cilt: 5 - Sayı: 1, 12–16. https://ajindex.com/articles/362760

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
  2. Andermann E, Scriver CR, Wolfe LS, et al. Genetic variants of Tay-Sachs disease: Tay-Sachs disease and Sandhoff’s disease in French Canadians, juvenile Tay-Sachs disease in Lebanese Canadians, and a Tay-Sachs screening program in the French- Canadian population. Prog Clin Biol Res 1977;18:161-88. Myrianthopoulos N. Some Epidemiological and Genetic Aspects of Tay Sachs Disease. (Academic Press, New York, 1962.). Sandhoff K. The GM2-gangliosidoses and the elucidation of the beta-hexosaminidase system. Adv Genet 2001;44:67-91.
  3. Gravel RA, Triggs-Raine BL, Mahuran DJ. Biochemistry and genetics of Tay-Sachs disease. Can J Neurol Sci 1991;18:419-23.
  4. Martino S, Cavalieri C, Emiliani C, et al. Restoration of theGM2 ganglioside metabolism in bone marrow derived stromal cells from Tay-Sachs disease animal model. Neurochem Res 2002;27:793-800.
  5. Martino S, Emiliani C, Tancini B, et al. Absence of metabolic cross-correction in Tay-Sachs cells:implications for gene therapy. J Biol Chem 2002;277:20177-84.
  6. Gravel R, Kaback M, Proia R, et al. The GM2 gangliosidosis. In: Scriver CR, Beaudet A, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of İnherited Disease. 8. New York: McGraw-Hill 2001;3827-76.
  7. Sandhoff K, Andreae U, Jatzkewitz H. Deficient hexozaminidase activity in an exceptional case of Tay– Sachs disease with additional storage of kidney globoside in visceral organs. Life Sci 1968;7:283-8.
  8. Krivit W, Desnick RJ, Lee J, et al. Generalized accumulation of neutral glycosphingolipids with GM2 ganglioside accumulation in the brain. Sandhoff disease [variant of Tay– Sachs disease]. Am J Med 1972;52:763-70. ohnsonWG. The clinical spectrum of hexosaminidase deficiency disease. Neurology 1981;31:1453-6.
  9. Maegawa G, Stockley T, Tropak M, et al. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics 2006;118:e1550-62. 13. Neudorfer O, Pastores GM, Zeng BJ, Gianutsos J, Zaroff CM, Kolodney EH. Late-onset Tay–Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med 2005;7:119-23.
  10. Federico A, Palmeri S, Malandrini A, Fabrizi G, Mondelli M, Guazzi GC. The clinical aspects of adult hexosaminidase deficiencies. Dev Neurosci 1991;13:280-7.
  11. Gravel RA, Kaback MM, Proia RL, Sandhoff K, Suzuki K, Suzuki K. The GM2 gangliosidoses. In: Valle D, Beaude